Gossamer Bio is advancing its late-stage clinical programs for seralutinib in pulmonary hypertension, with key Phase 3 study readouts and site activations anticipated. The company is also exploring strategic acquisitions to expand its pipeline.
Revenue from contracts with collaborators increased to $13.3 million from $9.5 million in the prior year period, driven by cost reimbursements.
positiveThe company expects its current cash, cash equivalents, and marketable securities of $180.2 million to be sufficient to fund operations into 2027.
positiveFirst clinical site activated for the registrational Phase 3 SERANATA Study in PH-ILD.
neutralStrategic option agreement signed to acquire Respira Therapeutics and its inhaled vardenafil candidate, minimizing near-term cash burn.
neutralNet loss widened significantly to $48.2 million from $30.8 million in the prior year period.
negativeBasic net loss per share increased to $0.21 from $0.14 in the prior year period.
negativeResearch and Development expenses increased by 30.5% year-over-year to $45.5 million.
attentionTotal assets decreased from $315.3 million at the end of 2024 to $208.8 million as of September 30, 2025.
negativeMargin metrics will be available once backend extracts data from insights_json
Special items are non-recurring events that may distort period-over-period comparisons. Analysts typically adjust for these when calculating normalized earnings.
We look forward to sharing top-line results from the PROSERA Phase 3 Study in February 2026.
We are encouraged by the engagement from the PH-ILD community as we begin to activate the first clinical sites in the SERANATA Phase 3 study.
We are grateful for the opportunity to collaborate closely with physicians and patients to better understand the challenges for those living with this challenging and under-treated disease.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.